A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema

Inclusion Criteria: * Upper arm lymphedema, single arm, stage 2, greater than 6 months duration * Male or female. * Ages 18-75. * Prior imaging by lymphoscintigraphy or magnetic resonance lymphangiography that confirms the presence of lymphedema in the affected limb OR, at screening, an affected:unaffected limb volume ratio of ≥1.1 with significant history of lymphedema * Consistent use of an appropriately sized compression garment for daytime use. * Willing to maintain a stable regimen of self-care from screening to end-of-study. * If a potential participant has undergone prior microvascular (vascular lymph node transfer, lymphaticovenous anastomosis) or debulking surgical intervention, at least one year must have elapsed prior to screening AND, at screening, an affected: unaffected limb volume ratio of ≥1.1. * Lymphedema therapy must be completed at least 8 weeks prior to screening. * Has received Covid-19 vaccine (Pfizer, Moderna or Johnson \& Johnson) * Ability to understand and the willingness to sign a written informed consent document. * . If the possibility of conception exits, agrees to use a medically acceptable method of contraception (both male and female) from the signing of the informed consent form through the entire study period; men or women who are surgically sterile (\> 6 months after surgery) or women who have been postmenopausal for at least 1 year are not considered to be of childbearing potential. Exclusion Criteria: * Concurrent participation in a c…